MorphoSys (MPSYF) 6-K Current report (foreign)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE13A-16 OR15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For March 2, 2020

Commission File Number1-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.

Form20-F  ☒            Form40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b):

Exhibits

99.1 FDA Accepts MorphoSys’ Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MORPHOSYS AG (Registrant)
Date: March 02, 2020	By:	/s/ Charlotte Lohmann
	Name:	Charlotte Lohmann
	Title:	Senior Vice President | General Counsel, Head of IP and Corporate Communications & IR a.i., Legal
	By:	/s/ Dr. Verena Kupas
	Name:	Dr. Verena Kupas
	Title:	Associate Director Corporate Communications and Investor Relations